Who are the top 10 play­ers that dom­i­nate the can­cer drug mar­ket? And who's grow­ing fastest?

Sev­erin Schwan, CEO Roche, speaks dur­ing a Feb­ru­ary 2017 press con­fer­ence in Basel, Switzer­land AP Im­ages

The stel­lar sales per­for­mance of new im­munother­a­py drugs is dri­ving a boom in in­vest­ment dol­lars flow­ing in­to the field. And it’s not hard to see why. Im­munother­a­py is de­liv­er­ing more sales, ear­li­er ex­its, and high­er re­turns on in­vest­ment for biotech in­vestors.

Last year, im­muno-on­col­o­gy drugs snagged 33% of all dol­lars spent on can­cer drugs. That’s de­spite the fact that these ther­a­pies on­ly make up 9% of all FDA-ap­proved on­col­o­gy drugs. These num­bers un­der­score a sim­ple fact in bio­phar­ma: If you’re a ma­jor play­er in the can­cer mar­ket, or want to be­come one, tar­get­ing im­muno-on­col­o­gy has be­come one of the fa­vorite strate­gies for grow­ing sales — quick­ly.

In this spe­cial re­port, we de­cid­ed to give you all an overview of the biggest play­ers in the can­cer area, in­clud­ing their suc­cess­es, what’s top of mind in I/O, and the chal­lenges that lie ahead for the top 10 com­pa­nies. In­cludes charts and a ta­ble of se­lect late-stage im­muno-on­col­o­gy ther­a­pies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER